person · Reporting owner

Phillips Matthew V

Disclosed activity across 1 company

Tapewire entity: 154300
SEC CIK: 0001729197

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Avalo Therapeutics, Inc.CERC · Entity 4936	Chief Commercial Officer	August 23, 2019	October 21, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Avalo Therapeutics, Inc.

Report date August 23, 2019 · Filed October 21, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy LLC	512,500	Reported balance After 2019-08-23 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2019-08-23 · Grant · Acquired 512,500 · Balance 512,500 F1: Acquired pursuant to the Settlement Agreement effective August 23, 2019 by and among MVP Ventures, LLC, Freemantle LLC and LRS International LLC, in exchange for the settlement and termination of Freemantle LLC's and LRS International LLC's certain interests in the Issuer. F2: MVP Ventures LLC ("MVP") is the record holder of the securities. The reporting person is the founder and principal of MVP and may be deemed to beneficially own the securities held by MVP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	1,020	Reported balance Holding disclosure · report date 2019-08-23 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,020
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 · Expires 2027-11-17	Direct	100,000	Reported balance Holding disclosure · report date 2019-08-23 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 100,000 F3: One fourth of the shares subject to the stock option will vest on November 17, 2018, and the remaining three-fourths of the shares subject to the stock option will vest in substantially equal monthly installments over the following 36 months, provided the Reporting Person is then still providing continuous service as an employee, director or consultant.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.21 · Expires 2028-01-22	Direct	100,000	Reported balance Holding disclosure · report date 2019-08-23 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 100,000 F4: One fourth of the shares subject to the stock option will vest on January 22, 2019, and the remaining three-fourths of the shares subject to the stock option will vest in substantially equal monthly installments over the following 36 months, provided the Reporting Person is then still providing continuous service as an employee, director or consultant.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.22 · Expires 2029-04-01	Direct	145,000	Reported balance Holding disclosure · report date 2019-08-23 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 145,000 F5: One fourth of the shares subject to the stock option will vest on April 1, 2020, and the remaining three-fourths of the shares subject to the stock option will vest in substantially equal monthly installments over the following 36 months, provided the Reporting Person is then still providing continuous service as an employee, director or consultant.

Filing footnotes · ownership attribution and instrument terms

F1: Acquired pursuant to the Settlement Agreement effective August 23, 2019 by and among MVP Ventures, LLC, Freemantle LLC and LRS International LLC, in exchange for the settlement and termination of Freemantle LLC's and LRS International LLC's certain interests in the Issuer.

F2: MVP Ventures LLC ("MVP") is the record holder of the securities. The reporting person is the founder and principal of MVP and may be deemed to beneficially own the securities held by MVP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F3: One fourth of the shares subject to the stock option will vest on November 17, 2018, and the remaining three-fourths of the shares subject to the stock option will vest in substantially equal monthly installments over the following 36 months, provided the Reporting Person is then still providing continuous service as an employee, director or consultant.

F4: One fourth of the shares subject to the stock option will vest on January 22, 2019, and the remaining three-fourths of the shares subject to the stock option will vest in substantially equal monthly installments over the following 36 months, provided the Reporting Person is then still providing continuous service as an employee, director or consultant.

F5: One fourth of the shares subject to the stock option will vest on April 1, 2020, and the remaining three-fourths of the shares subject to the stock option will vest in substantially equal monthly installments over the following 36 months, provided the Reporting Person is then still providing continuous service as an employee, director or consultant.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 23, 2019 Filed Oct 21, 2019 21:15 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	GrantCommon Stock	512,500	$1.07	$548,375.00	Disclosure SEC source: 0001578563-19-000034 · primary_doc.xml · nonDerivative · entry 1 Phillips Matthew V · CIK 0001729197 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By LLC Disclosed balance after: 512,500 F1 · shares: Acquired pursuant to the Settlement Agreement effective August 23, 2019 by and among MVP Ventures, LLC, Freemantle LLC and LRS International LLC, in exchange for the settlement and termination of Freemantle LLC's and LRS International LLC's certain interests in the Issuer. F2 · ownership.nature: MVP Ventures LLC ("MVP") is the record holder of the securities. The reporting person is the founder and principal of MVP and may be deemed to beneficially own the securities held by MVP. The reporting person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document
June 10, 2019 Filed Jun 12, 2019 01:04 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	PurchaseCommon Stock	523	$2.85	$1,489.24	Disclosure SEC source: 0001578563-19-000023 · primary_doc.xml · nonDerivative · entry 1 Phillips Matthew V · CIK 0001729197 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,020 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document
April 01, 2019 Filed Apr 2, 2019 23:36 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	GrantStock Option (Right to Buy) · Derivative	145,000	$0.00 Strike: $6.22	$0.00	Disclosure SEC source: 0001578563-19-000013 · primary_doc.xml · derivative · entry 2 Phillips Matthew V · CIK 0001729197 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2029-04-01 F1 · derivative.exercise_date: One fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months. Read SEC document
December 10, 2018 Filed Dec 11, 2018 22:22 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	PurchaseCommon Stock	497	$2.85	$1,415.21	Disclosure SEC source: 0001729197-18-000003 · primary_doc.xml · nonDerivative · entry 1 Phillips Matthew V · CIK 0001729197 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 497 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document
January 22, 2018 Filed Jan 24, 2018 21:46 UTC	Avalo Therapeutics, Inc. CERC · Entity 4936	GrantStock Option (right to buy) · Derivative	100,000	$0.00 Strike: $3.21	$0.00	Disclosure SEC source: 0001729197-18-000002 · primary_doc.xml · derivative · entry 1 Phillips Matthew V · CIK 0001729197 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-01-22 F1 · derivative.exercise_date: The grant shall vest one-fourth on each of the first, second, third and fourth anniversaries of the date of grant, provided Mr. Phillips is then an officer of the Company. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.